

AAMC Standardized Immunization Form

Last Name:	First N	ame:	Middle Initial:	
DOB:	Street Add	ress:		
Medical School:		City:		
Cell Phone:		State:		
Primary Email:	ZIP	Code:		
Student ID:				

of Rubella; or serologic proc	Maaalaa				Attached
Option 1	Vaccine	Date			
MMR -2 doses of MMR	MMR Dose #1		_		
vaccine	MMR Dose #2				
Option 2	Vaccine or Test	Date			
Maaalaa	Measles Vaccine Dose #1		s	Serology Results	
Measles -2 doses of vaccine or positive serology	Measles Vaccine Dose #2		Qualitative Titer Results:	Positive D Negative	
	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml	
	Mumps Vaccine Dose #1		Serology Results		
Mumps -2 doses of vaccine or positive serology	Mumps Vaccine Dose #2		Qualitative Titer Results:	Positive D Negative	
positive serology	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml	
			s	Serology Results	
Rubella -1 dose of vaccine or	Rubella Vaccine		Qualitative Titer Results:	Positive D Negative	
positive serology	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml	
Tetanus-diphtheria-per	tussis – One (1) dose of adult Tdap. If last Tdap is mo	re than 10 years old, p	orovide dates o	f last Td and Tdap	
	Tdap Vaccine (Adacel, Boostrix, etc)				
	Td Vaccine (if more than 10 years since last Tdap)				
Varicella (Chicken Pox)	- 2 doses of vaccine or positive serology				
	Varicella Vaccine #1		Serology Results		
	Varicella Vaccine #2		Qualitative Titer Results:	Positive Negative	
	Serologic Immunity (IgG antibody titer)		Quantitative Titer Results:	IU/ml	
Influenza Vaccine - 1 do	se annually each fall				
Defend here		Date			
Date of last dose	Flu Vaccine				
COVID-19 Vaccine - 1 dose of updated 2024-2025 COVID-19 vaccine if previously Date vaccinated with any COVID-19 Vaccine, administered >8 weeks after the last dose. Date					
	Pfizer-BioNTech COVID-19 vaccine				
	or Moderna COVID-19 vaccine				
	or Novavax COVID-19 vaccine (aged >12 yrs only)				



AAMC Standardized Immunization Form

Name: _____

(Last, First, Middle Initial)

(mm/dd/yyyy)

Hepatitis B Vaccination - 3 doses of Engerix-B, PreHevbrio, Recombivax HB or Twinrix vaccines or 2 doses of Heplisav-B vaccine followed by a <u>QUANTITATIVE</u> Hepatitis B Surface Antibody test drawn 4-8 weeks after last vaccine dose. A test titer ≥10mIU/mL is positive for immunity. If the test result is negative, CDC guidance recommends that HCP receive one or more additional doses of Hepatitis B vaccine up to completion of a second series, followed by a repeat titer test 4-8 weeks after the last vaccine dose. If a single additional vaccine dose does not elicit a positive test result, administer additional vaccine doses to complete the second series using the schedule approved for the primary series of a given product. If the Hepatitis B Surface Antibody test is negative (<10 mIU/mL) after receipt of 2 complete vaccine series, a "non-responder" status is assigned. See: http://dx.doi.org/10.15585/mmwr.rr6701a1 for additional information.				Copy Attached	
mornauon.	3-dose vaccines (Energix-B, PreHevbrio, Recombivax HB, Twinrix) or 2-dose vaccine (Heplisav-B)	3 Dose Series	2 Dose Series		
Primary Hepatitis B Series	Hepatitis B Vaccine Dose #1				
Heplisav-B only requires two	Hepatitis B Vaccine Dose #2				
doses of vaccine followed by antibody testing	Hepatitis B Vaccine Dose #3				
	QUANTITATIVE Hep B Surface Antibody Test		mIU/mI		
Additional doses of Hepatitis B Vaccine		3 Dose Series	2 Dose Series		
	Hepatitis B Vaccine Dose #4				
<u>Only If no response to</u> <u>primary series</u>	Hepatitis B Vaccine Dose #5				
Heplisav-B only requires two doses of vaccine followed by	Hepatitis B Vaccine Dose #6				
antibody testing	QUANTITATIVE Hep B Surface Antibody Test		mIU/mI		
Hepatitis B Vaccine Non-responder	If the Hepatitis B Surface Antibody test is negative (titer less than 10 mIU/mL) after a primary and repeat vaccine series, vaccine non-responders should be counseled and evaluated appropriately. Certain institutions may request signing an "acknowledgement of non-responder status" document before clinical placements.				
Additional Documentation					
<u>Some institutions</u> may have additional requirements depending upon rotation, school requirements or state law. Examples include meningitis vaccine which is mandated in some states if you live in dormitory style housing. If you will be participating in an international experience, you may also be required to provide proof of vaccines such as yellow fever or typhoid.					
Vaccination, Test or Ex	xamination	Date	Result or Interpre	etation	
Physical Exam (if required)					



Name:

AAMC Standardized Immunization Form

Date of Birth:

(Last, First, Middle Initial)

(mm/dd/yyyy)

TUBERCULOSIS (TB) SCREENING – All U.S. healthcare personnel are screened pre-placement for TB. Two kinds of tests are used to determine if a person has been infected with TB bacteria: the TB skin test (TST) and the TB blood test (IGRA). Results of the last two TSTs or one IGRA blood test are required regardless of prior BCG status. If the TST method is used, record the dates and results of two 1-step annual TSTs over the last two years, or of one 2-step TST protocol (two TSTs performed with the second TST placed at least 1 week after the first TST read date). In either series, the second TST must have been placed within the past 12 months prior to clinical duties, and must have been performed in the U.S. If you have a history of a positive TST (PPD) >10mm or a positive IGR blood test, please supply information regarding any evaluation and/or treatment below. You only need to complete ONE section, A or B. Skin test or IGRA results should not expire during proposed elective rotation dates or must be updated with the receiving institution prior to rotation. **Tuberculosis Screening History** Section A Date Placed Date Read Result Interpretation **TST #1** Pos Neg Equiv mm **TST #2** Des Deg Dequiv _mm Please complete only one TB section based on your history History of **Negative TB Skin Test or Blood** Test Date Result QuantiFERON TB Gold or T-Spot T-spots or QuantiFERON Positive Negative Indeterminate (Interferon Gamma Releasing Assay) TB Gold blood tests for tuberculosis QuantiFERON TB Gold or T-Spot Positive Negative Indeterminate Use additional (Interferon Gamma Releasing Assay) rows as needed Section B Date Placed Date Read Result Positive TST mm Date Result QuantiFERON TB Gold or T-Spot Positive Indeterminate Negative (Interferon Gamma Releasing Assay) History of Positive Skin Chest X-ray* *Provide documentation or result **Test or Positive Blood** Treated for latent TB infection (LTBI)? 🗆 Yes 🗖 No Test Date of Last Annual TB Symptom Questionnaire



Name:

AAMC Standardized Immunization Form

Date of Birth:

(Last, First, Middle Initial)

(mm/dd/yyyy)

Additional Information

MUST BE SIGNED BY A LICENSED HEALTHCARE PROFESSIONAL OR DESIGNEE:

Healthcare Professional Signature:		Date:
Printed Name:		Office Lice Only
Title:		Office Use Only
Address Line 1:		
Address Line 2:		
City:		
State:		
Zip:		
Phone:	() Ext:	
Fax:	()	
Email Contact:		

*Sources:

- 1. Hepatitis B In: Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Hamborsky J, Kroger A, Wolfe S, eds. 13th ed. Washington D.C. Public Health Foundation, 2015
- 2. Immunization of Health-Care Personnel: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR, Vol 60(7):1-45
- 3. CDC Guidance for Evaluating Health-Care Personnel for Hepatitis B Virus Protection and for Administering Postexposure Management, MMWR, Vol 62(RR10):1-19
- 4. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, MMWR Vol 67(1):1-31
- 5. Sosa LE, Nijie GL, Lobato MN, et.al. Tuberculosis Screening, Testing, and Treatment of U.S. Health Care Personnel: Recommendations from National Tuberculosis Controllers Association and CDC, 2019. MMWR2019;68:439-443. https://www.cdc.gov/mmwr/volumes/68/wr/mm6819a3.htm?s cid+mm6819a3 w